The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Interactions Between Haematopoietic, Bone, Vascular And Endocrine Systems Control Stem Cell Fate And Mobilization
Funder
National Health and Medical Research Council
Funding Amount
$380,558.00
Summary
Haemopoietic stem cells (HSC) normally reside in the bone marrow (BM) where they make blood and immune cells. We can force HSC to move from the BM into the blood, a process called mobilisation, used to collect large numbers of HSC for transplantation into cancer patients. My research involves identifying factors that control HSC fate within the BM (that is survival, growth, differentiation) and what happens during mobilisation to force them to leave with the aim of improving transplant success.
Klf5 Function In Normal And Leukaemic Haemopoiesis
Funder
National Health and Medical Research Council
Funding Amount
$609,924.00
Summary
Acute Myeloid Leukaemia (AML) is a devastating disease that affects both children and adults. New treatments that target particular genetic abnormalities are urgently needed. We have identified KLF5 as a gene that may control blood cell maturation. In AML patient samples we have found alterations of the KLF5 gene that may suppress its activity and contribute to the formation of leukaemia. These leukaemias may be good candidates for treatment with new drugs called methyltransferase inhibitors.